Background:A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to demonstrate the efficacy and a safety of Milvexian, an Oral Factor XIa Inhibitor, after a recent Acute Coronary SyndromeSponsor: Janssen, Bristol Myers Squibb, Johnson-JohnsonTrial Registration No:NCT05754957 (clinicaltrials.gov) LinkTrial Status:RecruitingEnrolling Centers:Worldwide:multicentricCore Study Team: